SG11201408074VA - Substituted picolinamide kinase inhibitors - Google Patents
Substituted picolinamide kinase inhibitorsInfo
- Publication number
- SG11201408074VA SG11201408074VA SG11201408074VA SG11201408074VA SG11201408074VA SG 11201408074V A SG11201408074V A SG 11201408074VA SG 11201408074V A SG11201408074V A SG 11201408074VA SG 11201408074V A SG11201408074V A SG 11201408074VA SG 11201408074V A SG11201408074V A SG 11201408074VA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- international
- avenue
- methods
- picolinamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261663510P | 2012-06-22 | 2012-06-22 | |
US13/841,867 US20140113931A1 (en) | 2012-06-22 | 2013-03-15 | Substituted picolinamide kinase inhibitors |
PCT/US2013/045987 WO2013192046A2 (fr) | 2012-06-22 | 2013-06-14 | Inhibiteurs substitués de picolinamide kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408074VA true SG11201408074VA (en) | 2015-01-29 |
Family
ID=49769665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408074VA SG11201408074VA (en) | 2012-06-22 | 2013-06-14 | Substituted picolinamide kinase inhibitors |
Country Status (10)
Country | Link |
---|---|
US (1) | US20140113931A1 (fr) |
EP (1) | EP2863905A4 (fr) |
JP (1) | JP2015523996A (fr) |
CN (1) | CN104602681A (fr) |
AU (1) | AU2013277473A1 (fr) |
CA (1) | CA2877469A1 (fr) |
HK (1) | HK1209316A1 (fr) |
IL (1) | IL235935A0 (fr) |
SG (1) | SG11201408074VA (fr) |
WO (1) | WO2013192046A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2932609A1 (fr) | 2013-12-05 | 2015-06-11 | Pharmacyclics Llc | Inhibiteurs de la tyrosine kinase de bruton |
BR112017025986A2 (pt) * | 2015-06-02 | 2018-08-14 | Pharmacyclics Llc | inibidores de tirosina quinase de bruton. |
AU2019407650B2 (en) | 2018-12-17 | 2022-10-27 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6797706B1 (en) * | 1999-06-09 | 2004-09-28 | Yamanouchi Pharmaceutical Co., Ltd. | Heterocyclecarboxamide derivative |
KR20170051521A (ko) * | 2008-04-16 | 2017-05-11 | 포톨라 파마슈티컬스, 인코포레이티드 | syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드 |
ES2632220T3 (es) * | 2009-06-15 | 2017-09-11 | Rigel Pharmaceuticals, Inc. | Inhibidores de moléculas pequeñas de tirosina cinasa del bazo (SYK) |
AU2011323484B2 (en) * | 2010-11-01 | 2016-10-06 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as Syk modulators |
CA2824544A1 (fr) * | 2011-01-21 | 2012-07-26 | Anil Vasudevan | Inhibiteurs picolinamides de kinases |
US9216173B2 (en) * | 2011-10-05 | 2015-12-22 | Merck Sharp & Dohme Corp. | 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
WO2014153280A1 (fr) * | 2013-03-22 | 2014-09-25 | Merck Sharp & Dohme Corp. | Inhibiteurs de tyrosine kinase de la rate (syk) contenant du 2-pyridyl carboxamide |
-
2013
- 2013-03-15 US US13/841,867 patent/US20140113931A1/en not_active Abandoned
- 2013-06-14 AU AU2013277473A patent/AU2013277473A1/en not_active Abandoned
- 2013-06-14 JP JP2015518468A patent/JP2015523996A/ja active Pending
- 2013-06-14 EP EP13807089.1A patent/EP2863905A4/fr not_active Withdrawn
- 2013-06-14 WO PCT/US2013/045987 patent/WO2013192046A2/fr active Application Filing
- 2013-06-14 CA CA2877469A patent/CA2877469A1/fr not_active Abandoned
- 2013-06-14 SG SG11201408074VA patent/SG11201408074VA/en unknown
- 2013-06-14 CN CN201380042757.0A patent/CN104602681A/zh active Pending
-
2014
- 2014-11-27 IL IL235935A patent/IL235935A0/en unknown
-
2015
- 2015-10-12 HK HK15109941.4A patent/HK1209316A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2013192046A2 (fr) | 2013-12-27 |
EP2863905A2 (fr) | 2015-04-29 |
US20140113931A1 (en) | 2014-04-24 |
JP2015523996A (ja) | 2015-08-20 |
EP2863905A4 (fr) | 2015-12-16 |
IL235935A0 (en) | 2015-01-29 |
HK1209316A1 (en) | 2016-04-01 |
CA2877469A1 (fr) | 2013-12-27 |
AU2013277473A1 (en) | 2015-02-05 |
CN104602681A (zh) | 2015-05-06 |
WO2013192046A3 (fr) | 2014-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408232RA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
SG11201809299QA (en) | Formulations of an lsd1 inhibitor | |
SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201804309PA (en) | Antibody molecules to april and uses thereof | |
SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
SG11201407533SA (en) | Antiviral compounds | |
SG11201407981RA (en) | Compositions comprising an anti-pdgf aptamer and a vegf antagonist | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
SG11201407372UA (en) | Nampt inhibitors | |
SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
SG11201407115XA (en) | Carboxylic acid compounds | |
SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
SG11201408133TA (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto |